0000000000551606
AUTHOR
Miguel Munoz
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…
Termination of a set of rules modulo a set of equations
The problem of termination of a set R of rules modulo a set E of equations, called E-termination problem, arises when trying to complete the set of rules in order to get a Church-Rosser property for the rules modulo the equations. We first show here that termination of the rewriting relation and E-termination are the same whenever the used rewriting relation is E-commuting, a property inspired from Peterson and Stickel’s E-compatibility property. More precisely, their results can be obtained by requiring termination of the rewriting relation instead of E-termination if E-commutation is used instead of E-compatibility. When the rewriting relation is not E-commuting, we show how to reduce E-t…